Maze Therapeutics, Inc. (MAZE) Stock Statistics & Valuation Metrics

Maze Therapeutics, Inc. has a market cap or net worth of $585.41M. The enterprise value is $298.52M.

Maze Therapeutics, Inc. has 43,850,883 shares outstanding. The number of shares has decreased by -2.65% in one year.

Maze Therapeutics, Inc.’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is 24.58%.

The current PE Ratio of Maze Therapeutics, Inc. is ―. Maze Therapeutics, Inc.’s PEG ratio is ―.

In the last 12 months, Maze Therapeutics, Inc. had revenue of 167.50M and earned 52.23M in profits. Earnings per share was 0.08.

In the last 12 months, operating cash flow was -105.22M and capital expenditures -1.40M, giving a free cash flow of -106.63M billion.

Maze Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Maze Therapeutics, Inc. upcoming earnings date is Aug 12, 2025, Before Open (Confirmed).

Maze Therapeutics, Inc. as a current ratio of 9.76, with Debt / Equity ratio of 9.54%

In the past 12 months, Maze Therapeutics, Inc. has paid 1.17M in taxes.

Maze Therapeutics, Inc. EV to EBITDA ratio is 8.68, with an EV/FCF ratio of 7.06.

Maze Therapeutics, Inc. has $264.54M in cash and marketable securities with $25.01M in debt, giving a net cash position of -$239.53M billion.

Gross margin is 18.48%, with operating margin of 34.38%, and net profit margin of 31.18%.

The average price target for Maze Therapeutics, Inc. is $26.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy